GILEAD SCIENCES INC (GILD)

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks

Regulators are already on the case, and their findings will have financial impacts.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $79.02, marking a +1.24% move from the previous day.

Gilead Sciences on track to snap its six-day winning streak (NASDAQ:GILD)

Gilead Sciences experienced its first decline in six days, slipping 1.60% to $78.09.

Gilead Sciences on track to snap six-day winning streak

Gilead Sciences experienced its first decline in six days, slipping 1.60% to $78.09.

A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene

Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UPDATE 1-Merck's lung cancer drug combo fails to meet trial goal

Merck said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not meet the main goal in a mid-stage study. Merck's experimental drug, vibostolimab, in combination with its blockbuster drug Keytruda, failed to meaningfully slow disease progression and improve overall survival in patients with metastatic non-small-cell lung cancer. Gilead Sciences, Roche and GSK are among the drugmakers looking to grab a share of the lucrative cancer market focused on a protein believed to help cancer cells thwart immune system detection.

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

3 Biotech Stocks That Could Be Multibaggers in the Making

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Gilead unit Kite Pharma to lay off 300 workers; impact on former Tmunity operations in Philadelphia not disclosed

2 Biotech Stocks You Can Buy and Hold for the Next Decade

These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

UPDATE 1-US FDA investigating safety risk of CAR-T therapies

The U.S. Food and Drug Administration said on Tuesday it was investigating the safety risk of CAR-T therapies made by companies such as Gilead and Johnson & Johnson after receiving reports of adverse events in patients. T-cell malignancies are a group of diseases caused by abnormal growth in T-cell, a type of white blood cell that helps the body in fighting infections. The FDA's investigation is also looking into currently approved cancer therapies in this class, including those from Bristol-Myers Squibb and Novartis AG.

FDA probing serious risk of T-cell malignancies in CAR-T cell therapy patients

The FDA on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies. Read more here.

FDA investigating serious risk of T-cell malignancies in CAR-T cell therapy patients

The FDA on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies. Read more here.

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later

There's no time like the present to buy these stocks.

Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals

Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.

A Hollywood director took millions of dollars in Netflix funding and used it to trade options and crypto, report says. Here's a closer look at how he used the cash.

"47 Ronin" director Carl Erik Rinsch reportedly used production funds from Netflix to place bets on Gilead Sciences stock, the S&P 500, and dogecoin.

Aurinia Pharma jumps amid takeover speculation

Aurinia Pharmaceuticals (AUPH) experiences a 7.3% surge amidst takeover rumors, fueled by a reported visit from Gilead Sciences (GILD) corporate jet.

The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics

Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.

Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead

Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

The companies will work together on treatments for multiple myeloma and lymphomas.

Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration

The transaction includes cash the smaller biotech can use to develop its business.

Arcellx stock gains as Gilead invests $200M (NASDAQ:ACLX)

Arcellx (ACLX) shares rise as Gilead (GILD) agrees to make a $200M equity investment in the immunotherapy developer as part of an expanded deal. Read more here.

: Arcellx’s stock set to surge after Gilead makes $200 million investment at a 30% premium

Shares of Arcellx Inc. were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.’s Kite as...